【重大事项】 中国电力(02380)拟收购达州能源31%的股权 顺腾国际控股(00932)获主席张少辉折让约20%提全购要约 【财报数据】 华润置地(01109)前8月累计合同销售金额1368.0亿元 同比减少12.0% 越秀地产(00123)前8个月累计合同销售额约为730.11亿元 同比上升约3.7% 众安在线(06060)前8个月原保险保费收入总额约236.25亿元 同比增加6.36% 东吴水泥(00695)控股股东Goldview拟出售合共2.04亿股 港航香港将成为单一最大股东 石药集团(01093)：SYH2066片在中国获临床试验批准 广汽集团(02238)拟申请发行不超过150亿元的公司债券及150 亿元的中期票据 华泰证券(06886)拟发行不超过60亿元公司债券 方舟健客(06086)：H2H 大会消息非内幕消息 不知股价上涨原因 华检医疗(01931)设立合资公司 透过"ETHK"核心品牌深化全球链上金融生态战略布局 德林控股(01709)与赢家时尚(03709)订立战略合作及投资协议 ...

董事会亦留意到，公司就其于2025年9月10日举行的第十届H2H医疗服务生态大会而刊发的新闻稿，其 中包括若干公司最新消息，包括(i)公司发布专有「杏石」大模型("杏石大模型")作为其五项旗舰应用(AI 用药助手、AI健康管家、AI医生助手、AI学术助手及AI搜索)的基石，赋能先进临床诊断支援及个性化 慢病管理；(ii)与信达生物制药("信达")达成战略合作伙伴关系，整合方舟H2H数字健康生态系统与信达 体重管理疗法管线，初步利用公司之杏石大模型，为信达的玛仕度肽提供个性化数字维护及依从性支 持，在中国快速增长的体重管理市场提高患者的疗效；及(iii)与浙江大塚制药有限公司("大塚")展开战略 合作，结合公司的AI技术优势及大塚的创新药组合，共同开发覆盖药物支援服务、针对性病患外展项 目及健康教育计划的全方位数字解决方案。 经作出在相关情况下有关公司的该等合理查询后，董事会确认(i)新闻稿所含资料并不构成根据上市规则 第13.09(2)条或香港法例第571章证券及期货条例第XIVA部项下之内幕消息条文所规定之内幕消息；及 (ii)其亦并不知悉股份交易价格上升之任何理由，或为避免股份出现虚假市场而须作出公告之任 ...

Core Viewpoint - Ark Health (06086) has observed a recent increase in its share price on the Hong Kong Stock Exchange as of September 12, 2025, following the announcement of its strategic initiatives and partnerships in the healthcare sector [1]. Group 1: Company Developments - The company has launched its proprietary "Xing Shi" large model, which serves as the foundation for five flagship applications, including AI medication assistant, AI health manager, AI doctor assistant, AI academic assistant, and AI search, aimed at enhancing clinical diagnostic support and personalized chronic disease management [1]. - Ark Health has formed a strategic partnership with Innovent Biologics to integrate its H2H digital health ecosystem with Innovent's weight management therapy pipeline, utilizing the "Xing Shi" model to provide personalized digital maintenance and adherence support for Innovent's Ma Shidu peptide in China's rapidly growing weight management market [1]. - The company has also entered into a strategic collaboration with Zhejiang Otsuka Pharmaceutical Co., combining its AI technology advantages with Otsuka's innovative drug portfolio to jointly develop comprehensive digital solutions covering drug support services, targeted patient outreach programs, and health education initiatives [1]. Group 2: Regulatory Confirmation - The board has confirmed that the information contained in the press release does not constitute inside information as defined under the Listing Rules and relevant securities regulations, and it is unaware of any reasons for the increase in share price or any information that needs to be disclosed to avoid creating a false market in its shares [2].

Group 1 - The company, Ark Health (06086), has observed a recent increase in its share price on the Hong Kong Stock Exchange as of September 12, 2025 [1] - The company announced its proprietary "Xing Shi" large model, which serves as the foundation for five flagship applications aimed at enhancing clinical diagnostic support and personalized chronic disease management [1] - A strategic partnership has been established with Innovent Biologics to integrate Ark's H2H digital health ecosystem with Innovent's weight management therapy pipeline, utilizing the "Xing Shi" model for personalized digital maintenance and compliance support in China's growing weight management market [1] - The company has also formed a strategic collaboration with Zhejiang Otsuka Pharmaceutical Co., Ltd. to develop comprehensive digital solutions that combine AI technology with Otsuka's innovative drug portfolio, focusing on drug support services, targeted patient outreach programs, and health education initiatives [1] Group 2 - The board confirmed that the information contained in the press release does not constitute insider information as defined under the relevant listing rules and securities regulations [2] - The board is not aware of any reasons for the increase in share price or any information that would require disclosure to prevent a false market in the shares [2]

Core Insights - Guangdong Province has registered 6 new generative artificial intelligence services, bringing the total to 23 registered services as of July 17 [1] Group 1: New Registrations - The newly registered generative AI services include: 1. Guangfa GPT Model by Guangfa Securities Co., Ltd., registered on July 10, 2025 [3] 2. Anli AI Assistant by Amway (China) Daily Products Co., Ltd., registered on July 10, 2025 [3] 3. Samsung Smart Assistant by Guangzhou Samsung Communication Technology Research Co., Ltd., registered on July 17, 2025 [3] 4. Xing Shi Large Model by Guangzhou Ark Cloud Health Information Technology Group Co., Ltd., registered on July 17, 2025 [3] 5. Zhongchang Kangda Education Large Model by Guangzhou Zhongchang Kangda Information Technology Co., Ltd., registered on July 17, 2025 [3] 6. Zhilv Plant Large Model by Guangzhou Jingli Garden Fragrance Technology Co., Ltd., registered on July 17, 2025 [3]